Abstract:
In recent years, molecular bioregulatory drugs have come into practice
for the treatment of OA. Bioregulatory drugs consist of several components (usually of
natural origin) that affect many processes simultaneously as part of the anti inflammatory response. Recently, the use of bioregulatory drugs Traumel S and Zeel
T in the pathogenetic treatment of OA has justified in clinical practice. Traumel S is a
bioregulatory agent of plant and mineral origin, containing 14 components, having
anti-inflammatory, exudative, regenerating, analgesic and immunomodulatory effects.
The purpose of the study is to evaluate the effectiveness of bioregulatory drugs in
the treatment of osteoarthritic patients in the climacteric period with endothelial
dysfunction. From 2020 to 2022, 105 climacteric female patients with a confirmed
diagnosis of OA of the knee joint, registered in the arthrological IADC department of
the multidisciplinary clinic of the Tashkent Medical Academy (TMA), receiving inpatient treatment in the departments of cardiorheumatology and rheumatology, were
involved in this research work. They analyzed the clinical course of the disease and the
results of laboratory and instrumental examinations. For prospective analysis, the
patients were divided into two groups: Group I consisted of female patients with
premenopausal OA. Group II consisted of postmenopausal female patients with OA
during menopause.
In the obtained results, the clinical and laboratory activity indicators of the disease
reliably decreased in a statistically significant manner in the group of patients treated
with bioregulatory drugs compared to traditional treatment. Also, indicators of
endothelial dysfunction were improved. In UVD and MRI, degenerative changes in
bones and joints showed positive dynamics.
In conclusion, in the treatment of OA patients in the climacteric period, the use of
bioregulatory drugs (Traumel S and Zeel T) in addition to traditional treatment reduces
the frequency of degenerative changes in the joints by reducing the clinical laboratory
activity level of the disease, improving endothelial dysfunction, and improving the
quality of life of patients.
